StockNews.AISignal intelligence
NRx Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public NRXP signals with their source context and measured market impact. Open any signal for its permanent analysis page.
NRx Pharmaceuticals is scheduled to announce its Q1 earnings on May 18, with analysts projecting a reduced loss per share of 11 cents. Additionally, the company recently received FDA clearance for a clinical trial of NRX-101, which may enhance its appeal to investors, leading to further stock price movements.
View signal analysisNRXP developing NRX-101 as a breakthrough therapy for suicidal depression. FDA accepted ANDA for preservative-free IV ketamine, KETAFREE™. Analyst D. Boral sets $34 price target for NRXP. New indication for NRX-101 enhances treatment efficacy with TMS. NRXP expects over 1 million TMS treatments annually by 2030.
View signal analysisNRXP develops NRX-101 for treatment-resistant bipolar depression. FDA received NRXP's ANDA for KETAFREE™, target goal date July 29, 2026. Current ketamine market valued at $750 million, KETAFREE™ aims to disrupt. NRXP expanding clinical operations with multiple facilities in Florida. D. Boral research sets a $34 price target for NRXP.
View signal analysisFDA gave supportive correspondence for KETAFREE ANDA; GDUFA target Q2 2026. NRXP received expanded Fast Track for NRX-100 and progressed NDA work. Three Florida HOPE clinics now revenue-generating; six more clinics planned. Manufactured commercial lots of NRX-100 and KETAFREE with three-year shelf life. Nonbinding license terms propose >$300M milestones plus tiered double-digit royalties.
View signal analysis